Valuation: Relay Therapeutics, Inc.

Market Cap 4.26B 3.65B 3.41B 3.12B 5.86B 408B 5.94B 40.31B 15.71B 205B 15.99B 15.64B 677B P/E 2026 *
-12.1x
P/E 2027 * -12x
Enterprise Value 3.69B 3.16B 2.95B 2.7B 5.08B 353B 5.15B 34.91B 13.61B 177B 13.85B 13.55B 586B EV / Sales 2026 *
466x
EV / Sales 2027 * 231x
Free-Float
91.35%
Yield 2026 *
-
Yield 2027 * -
1 day-1.32%
1 week-2.11%
Current month+3.24%
1 month+0.73%
3 months+42.31%
6 months+123.45%
Current year+129.79%
1 week 19.18
Extreme 19.18
21.27
1 month 17.71
Extreme 17.71
21.27
Current year 7.01
Extreme 7.01
21.27
1 year 3.44
Extreme 3.4446
21.27
3 years 1.78
Extreme 1.775
21.27
5 years 1.78
Extreme 1.775
38.15
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 2017-02-28
Director of Finance/CFO 49 2018-03-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 2015-05-03
Director/Board Member 66 2016-06-30
Director/Board Member 52 2017-02-28
Date Insider Type Main position Quantity % Market Cap.
8/17/26 Sell

Chief Executive Officer

-48,199 0.0221%
8/14/26 Sell

Chief Financial Officer

-17,717 0.0081%
7/28/26 Sell

Chief Financial Officer

-1,459 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
-1.32%-2.11%+470.09%+82.19% 4.26B
+1.09%+5.26%+4.44%+26.03% 51.61B
-1.07%+2.82%+474.18%+601.24% 44.89B
+1.47%+9.79%+40.15%+21.21% 42.77B
+1.44%+7.77%+19.27%+90.94% 42.58B
-0.93%-4.33%+17.87%+51.96% 31.82B
+1.32%+7.30%+36.93%+152.36% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+7.12%+35.49% 14.76B
+1.28%+5.41%+91.01%+46.93% 14.09B
Average +0.27%+3.78%+129.01%+123.15% 28.07B
Weighted average by Cap. +0.46%+4.61%+108.49%+147.45%

Financials

2026 *2027 *
Net sales 7.91M 6.77M 6.33M 5.8M 10.89M 757M 11.03M 74.85M 29.17M 380M 29.7M 29.05M 1.26B 16.53M 14.16M 13.24M 12.12M 22.76M 1.58B 23.06M 156M 60.98M 794M 62.08M 60.72M 2.63B
Net income -323M -277M -259M -237M -445M -30.92B -451M -3.06B -1.19B -15.52B -1.21B -1.19B -51.34B -346M -297M -277M -254M -477M -33.14B -483M -3.28B -1.28B -16.63B -1.3B -1.27B -55.04B
Net Debt -571M -489M -457M -418M -786M -54.62B -796M -5.4B -2.1B -27.41B -2.14B -2.1B -90.71B -442M -378M -354M -324M -608M -42.3B -617M -4.18B -1.63B -21.23B -1.66B -1.62B -70.25B
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
202
Date Price Change Volume
26-08-21 US$19.44 -1.32% 2,965,869
26-08-20 US$19.70 -5.01% 2,788,838
26-08-19 US$20.74 +0.63% 2,101,614
26-08-18 US$20.61 -0.29% 2,227,625
26-08-17 US$20.67 +4.08% 1,835,259
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
19.44USD
Average target price
27.08USD
Spread / Average Target
+39.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLAY Stock